Brief: Esperion Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk
02/12/2024 13:26
Dec 2 (Reuters) - Esperion Therapeutics Inc ESPR.O :
* ESPERION: NEW DRUG SUBMISSIONS IN CANADA FOR NEXLETOL AND
NEXLIZET TREATMENTS TO REDUCE LDL-C AND CARDIOVASCULAR RISK
Source text: ID:nGNXc5TH9C
Further company coverage: ESPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi